As discussed, the most compelling rationale for clinical use of IKKβ inhibitors appears to be in combination therapies and/or as part of a targeted delivery approach, particularly in cancers exhibiting clear addiction to constitutive NF-κB signalling. The gene discussed is NFKB1; the disease is cancer.